As the pharmacist pipeline tightens, leaders from UC Davis Health, UCSF Health, and Sutter Health say financial sustainability now depends as much on capacity as on cost.
News|Videos|July 16, 2026
The Economics of Cell and Gene Therapy: Managing the Cost, Realizing the Value
Advertisement
Cell and gene therapies are moving from scientific breakthroughs to real-world treatment options, offering unprecedented potential for patients while creating new challenges for payers, providers, manufacturers and policymakers.
As more therapies enter the market with multimillion-dollar price tags and the promise of long-term clinical benefit, questions surrounding affordability, reimbursement, financial risk and patient access are becoming increasingly urgent.
Managed Healthcare Executive®, The American Journal of Managed Care® and Pharmacy Benefit Management Institute® partnered on this discussion to examine the economic realities shaping the future of cell and gene therapy.
Advertisement
Related to this article
GLP-1 use in adults 65 and older with MASLD was linked to a 45% lower risk of death, and a 28% lower risk of hepatic decompensation, a new Houston Methodist Research Institute study shows.
New data from Sutter Health suggest the real gap in GLP-1 access is physician awareness, not insurance coverage — and fixing it closed outcome disparities across every racial and ethnic group.
Research findings presented at the CHEST meeting show that false positives may make patients more adherent to screening. Qualitative research shows that patients want more explanation and results communicated verbally.
David Chen, PharmD, explains how physician-led formulary decisions — not rebates — power Kaiser Permanente’s biosimilar strategy, and why he thinks other health systems could do the same.
10 research abstracts presented at the CHEST meeting are split on whether hospital admission during the weekend is assoicated with worse outcomes than admission on weekdays.
Research findings scheduled to be presented at the CHEST meeting show broad positive cardiopulmonary effects from GLP-1s and an association with a reduced risk of acute respiratory failure.
Chad Hatfield, Pharm.D., of UC Davis Health, says 340B savings fund free clinics and mental health care that could shrink as the program’s future shifts.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Kaiser’s formulary chief makes his case for a ‘total value’ model on biologics | HSES 2026
2
Long-acting lenacapavir plus cabotegravir kept all 46 patients with HIV virally suppressed in recent trial
3
More pluses for GLP-1s for obstructive sleep apnea | CHEST 2026
4
Chad Hatfield, Pharm.D., on the 340B uncertainty facing health systems| HSES 2026
5